According to the research report, the global cancer supportive care drugs market size is expected to touch USD 25.78 Billion by 2032, from USD 25.78 Billion in 2022, growing with a significant CAGR of 2.09% from 2023 to 2032.
The cancer supportive care drugs report
offers a comprehensive study of the current state expected at the major
drivers, market strategies, and key vendors’ growth. The report presents
energetic visions to conclude and study the market size, market hopes, and
competitive surroundings. The research also focuses on the important
achievements of the market, research & development, and regional growth of
the leading competitors operating in the market. The current trends of the
global cancer supportive care drugs in conjunction with the geographical
landscape of this vertical have also been included in this report.
The report offers intricate dynamics about
different aspects of the global cancer supportive care drugs market, which aids
companies operating in the market in making strategic development decisions.
The study also elaborates on significant changes that are highly anticipated to
configure growth of the global cancer supportive care drugs during the forecast
period. It also includes a key indicator assessment that highlights growth
prospects of this market and estimates statistics related to growth of the
market in terms of value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/2665
| Report Coverage | Details |
| Market Size in 2023 | USD 21.4 Billion |
| Market Size by 2032 | USD 25.78 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 2.09% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Therapeutic Class, By Application and By Distribution Channel |
This study covers a detailed segmentation
of the global cancer supportive care drugs market, along with key information
and a competition outlook. The report mentions company profiles of players that
are currently dominating the global cancer supportive care drugs market,
wherein various developments, expansions, and winning strategies practiced and
implemented by leading players have been presented in detail.
Key Players
- Merck & Co.
- Novartis AG
- F. Hoffman-La Roche AG
- Johnson & Johnson
- GlaxoSmithKline Plc
- Helsin Healthcare SA
- Baxter International Inc
Market Segmentation
- ESA (Erythropoiesis Stimulating Agents)
- G-CSFs (Granulocyte Colony Stimulating Factors)
- Antiemetics
- Bisphosphonates
- Opioids
- NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
By Application
- Breast Cancer
- Stomach Cancer
- Colorectal Cancer
- Liver Cancer
- Prostate Cancer
By Distribution Channel
- Drug pharmacies/ Retail pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global cancer supportive care drugs report is based
on detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market association
publications, and company websites to obtain the necessary understanding of the
global cancer supportive care drugs market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Supportive Care Drugs Market
5.1. COVID-19 Landscape: Cancer Supportive Care Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Supportive Care Drugs Market, By Therapeutic Class
8.1. Cancer Supportive Care Drugs Market Revenue and Volume, by Therapeutic Class, 2023-2032
8.1.1 ESA (Erythropoiesis Stimulating Agents)
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. G-CSFs (Granulocyte Colony Stimulating Factors)
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Antiemetics
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Bisphosphonates
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Opioids
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
8.1.6. NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
8.1.6.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Cancer Supportive Care Drugs Market, By Application
9.1. Cancer Supportive Care Drugs Market Revenue and Volume, by Application, 2023-2032
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Stomach Cancer
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Colorectal Cancer
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
9.1.4. Liver Cancer
9.1.4.1. Market Revenue and Volume Forecast (2020-2032)
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Cancer Supportive Care Drugs Market, By Distribution Channel
10.1. Cancer Supportive Care Drugs Market Revenue and Volume, by Distribution Channel, 2023-2032
10.1.1. Drug pharmacies/ Retail pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Hospital Pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Cancer Supportive Care Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.1.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.2.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.3.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2020-2032)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. Merck & Co.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffman-La Roche AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson & Johnson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. GlaxoSmithKline Plc
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Helsin Healthcare SA
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Baxter International Inc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments